Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 7/20 | 0.46 |
| ▸ | RAB9A | P51151 | 3/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.43 |
| ▸ | NPC1 | O15118 | 3/20 | 0.42 |
| ▸ | POLB | P06746 | 1/20 | 0.42 |
| ▸ | BAZ1A | Q9NRL2 | 3/20 | 0.41 |
| ▸ | TP53 | P04637 | 2/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | NSD2 | O96028 | 1/20 | 0.40 |
| ▸ | NQO2 | P16083 | 1/20 | 0.39 |
| ▸ | APP | P05067 | 2/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | GLA | P06280 | 1/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
| ▸ | THRB | P10828 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.38 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4269185 | 0.83 | ALDH1A1 (0.54) | MAPTRAB9AALDH1A1NPC1POLB | |
| SCHEMBL764255 | 0.78 | NPC1 (0.50) | MAPTRAB9AALDH1A1NPC1POLB | |
| SCHEMBL8828774 | 0.75 | CNR1 (0.43) | MAPTRAB9AALDH1A1NPC1POLB | |
| SCHEMBL1291431 | 0.74 | NPC1 (0.42) | MAPTRAB9AALDH1A1NPC1POLB | |
| SCHEMBL2211494 | 0.74 | ALDH1A1 (0.46) | MAPTRAB9AALDH1A1NPC1POLB | |
| SCHEMBL1292012 | 0.74 | SMN1; SMN2 (0.46) | MAPTRAB9AALDH1A1NPC1POLB | |
| SCHEMBL10630197 | 0.74 | BAZ1A (0.47) | MAPTRAB9AALDH1A1NPC1POLB | |
| SCHEMBL507524 | 0.74 | PRMT3 (0.45) | MAPTRAB9AALDH1A1NPC1POLB | |
| SCHEMBL508108 | 0.74 | PRMT3 (0.42) | MAPTRAB9AALDH1A1NPC1POLB | |
| SCHEMBL29567889 | 0.74 | PRMT3 (0.45) | MAPTRAB9AALDH1A1NPC1POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 59 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1243178-A1 | Method for protecting crops from parasitic weeds using benzothiazole derivatives | KOGEL, KARL-HEINZ, Prof., Dr. (DE) | 2002-09-25 | — | — | EP | claimed |
| US-6281168-B1 | PROTECTING CEREAL CROPS | AMERICAN CYANAMID CO. | 2001-08-28 | — | — | US | claimed |
| EP-1021953-A1 | Herbicidal compositions and method of safening herbicides using benzothiazole derivatives | American Cyanamid Company (US) | 2000-07-26 | — | — | EP | claimed |
| WO-2023014296-A2 | MOLECULAR GLUE AND SALL4 DEGRADER | NATIONAL UNIVERSITY OF SINGAPORE (SG) | 2023-02-09 | — | — | WO | disclosed |
| US-11229646-B2 | Method for treating gonorrhea with (2R)-2-({4-[(3,4-dihydro-2H-pyrano[2,3-C]pyridin-6-ylmethyl)amino]-1-piperidinyl}methyl)-1,2-dihydro-3H,8H-2A,5,8A-triazaacenaphthylene-3,8-dione | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED | 2022-01-25 | — | — | US | disclosed |
| WO-2022015624-A1 | SUBSTITUTED DIHYDROPYRAZINEDIONES AS MODULATORS OF THE NMDA RECEPTOR | SCHRÖDINGER, INC. (US) | 2022-01-20 | — | — | WO | disclosed |
| US-20200330462-A1 | TRICYCLIC NITROGEN CONTAINING COMPOUNDS FOR TREATING NEISSERIA GONORRHOEA INFECTION | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2020-10-22 | — | — | US | disclosed |
| US-10702521-B2 | Methods for treating neisseria gonorrhoeae infection with substituted 1,2-dihydro-2A,5,8A-triazaacenaphthylene-3,8-diones | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2020-07-07 | — | — | US | disclosed |
| EP-3639824-A1 | TRICYCLIC NITROGEN CONTAINING COMPOUNDS FOR TREATING NEISSERIA GONORRHOEA INFECTION | GlaxoSmithKline Intellectual Property Development Limited (GB) | 2020-04-22 | — | — | EP | disclosed |
| EP-3182973-B1 | TRICYCLIC NITROGEN CONTAINING COMPOUNDS FOR TREATING NEISSERIA GONORRHOEA INFECTION | GLAXOSMITHKLINE IP DEV LTD (GB) | 2019-09-18 | — | — | EP | disclosed |
| WO-2018010856-A1 | HRI ACTIVATORS USEFUL FOR THE TREATMENT OF CARDIOMETABOLIC DISEASES | UNIVERSITAT DE BARCELONA (ES) | 2018-01-18 | — | — | WO | disclosed |
| WO-2008116815-A2 | COMPOUNDS | GLAXO GROUP LIMITED (GB) | 2008-10-02 | — | — | WO | disclosed |
| WO-2008009700-A1 | DERIVATIVES AND ANALOGS OF N-ETHYLQUINOLONES AND N-ETHYLAZAQUINOLONES | GLAXO GROUP LIMITED (GB) | 2008-01-24 | — | — | WO | disclosed |
| WO-2008006648-A1 | SUBSTITUTED 1-METHYL-1H-QUINOLIN-2-ONES AND 1-METHYL-1H-1,5-NAPHTHYRIDIN-2-ONES AS ANTIBACTERIALS | GLAXO GROUP LIMITED (GB) | 2008-01-17 | — | — | WO | disclosed |
| WO-2008003690-A1 | AZATRICYCLIC COMPOUNDS AND THEIR USE | GLAXO GROUP LIMITED (GB) | 2008-01-10 | — | — | WO | disclosed |
| WO-2007118130-A2 | ANTIBACTERIAL AGENTS | GLAXO GROUP LIMITED (GB) | 2007-10-18 | — | — | WO | disclosed |
| WO-2007115947-A1 | PYRROLO-QUINOXALINONE DERIVATIVES AS ANTIBACTERIALS | GLAXO GROUP LIMITED (GB) | 2007-10-18 | — | — | WO | disclosed |
| EP-1243178-A1 | Method for protecting crops from parasitic weeds using benzothiazole derivatives | KOGEL, KARL-HEINZ, Prof., Dr. (DE) | 2002-09-25 | — | — | EP | disclosed |
| US-6281168-B1 | PROTECTING CEREAL CROPS | AMERICAN CYANAMID CO. | 2001-08-28 | — | — | US | disclosed |
| EP-1021953-A1 | Herbicidal compositions and method of safening herbicides using benzothiazole derivatives | American Cyanamid Company (US) | 2000-07-26 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200330462-A1 | TRICYCLIC NITROGEN CONTAINING COMPOUNDS FOR TREATING NEISSERIA GONORRHOEA INFECTION | NME2, NNMT, NGLY1 | MAPT 1672/4885RAB9A 3148/4885ALDH1A1 2255/4885 |
| US-10702521-B2 | Methods for treating neisseria gonorrhoeae infection with substituted 1,2-dihydro-2A,5,8A-triazaacenaphthylene-3,8-diones | DHPS, HSD17B11, GNE | MAPT 2757/4885RAB9A 1577/4885ALDH1A1 300/4885 |
| US-11229646-B2 | Method for treating gonorrhea with (2R)-2-({4-[(3,4-dihydro-2H-pyrano[2,3-C]pyridin-6-ylmethyl)amino]-1-piperidinyl}methyl)-1,2-dihydro-3H,8H-2A,5,8A-triazaacenaphthylene-3,8-dione | GMPS, GNE, DHPS | MAPT 2923/4885RAB9A 3356/4885ALDH1A1 1200/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.